JP4605798B2 - Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 - Google Patents

Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 Download PDF

Info

Publication number
JP4605798B2
JP4605798B2 JP2006507006A JP2006507006A JP4605798B2 JP 4605798 B2 JP4605798 B2 JP 4605798B2 JP 2006507006 A JP2006507006 A JP 2006507006A JP 2006507006 A JP2006507006 A JP 2006507006A JP 4605798 B2 JP4605798 B2 JP 4605798B2
Authority
JP
Japan
Prior art keywords
fragment
antibody
composition
seq
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006507006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006520781A5 (enExample
JP2006520781A (ja
Inventor
マーティン オフト，
テリル ケー． マククラナハン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2006520781A publication Critical patent/JP2006520781A/ja
Publication of JP2006520781A5 publication Critical patent/JP2006520781A5/ja
Application granted granted Critical
Publication of JP4605798B2 publication Critical patent/JP4605798B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2006507006A 2003-03-10 2004-03-09 Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 Expired - Fee Related JP4605798B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45367203P 2003-03-10 2003-03-10
PCT/US2004/007198 WO2004081190A2 (en) 2003-03-10 2004-03-09 Uses of il-23 agonists and antagonists; related reagents

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2007046287A Division JP2007197453A (ja) 2003-03-10 2007-02-26 Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
JP2010200382A Division JP2011032275A (ja) 2003-03-10 2010-09-07 Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用

Publications (3)

Publication Number Publication Date
JP2006520781A JP2006520781A (ja) 2006-09-14
JP2006520781A5 JP2006520781A5 (enExample) 2007-04-12
JP4605798B2 true JP4605798B2 (ja) 2011-01-05

Family

ID=32990805

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006507006A Expired - Fee Related JP4605798B2 (ja) 2003-03-10 2004-03-09 Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
JP2007046287A Pending JP2007197453A (ja) 2003-03-10 2007-02-26 Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
JP2010200382A Withdrawn JP2011032275A (ja) 2003-03-10 2010-09-07 Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
JP2013168870A Pending JP2014005286A (ja) 2003-03-10 2013-08-15 Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2007046287A Pending JP2007197453A (ja) 2003-03-10 2007-02-26 Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
JP2010200382A Withdrawn JP2011032275A (ja) 2003-03-10 2010-09-07 Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
JP2013168870A Pending JP2014005286A (ja) 2003-03-10 2013-08-15 Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用

Country Status (22)

Country Link
US (4) US7282204B2 (enExample)
EP (2) EP2108658B1 (enExample)
JP (4) JP4605798B2 (enExample)
CN (1) CN1759123B (enExample)
AT (1) ATE440864T1 (enExample)
AU (2) AU2004219625B9 (enExample)
BR (1) BRPI0408247A (enExample)
CA (1) CA2518262C (enExample)
CL (1) CL2004000467A1 (enExample)
CY (1) CY1109468T1 (enExample)
DE (1) DE602004022781D1 (enExample)
DK (1) DK1601694T3 (enExample)
ES (1) ES2330220T3 (enExample)
MX (1) MXPA05009717A (enExample)
NO (1) NO20054630L (enExample)
NZ (2) NZ541898A (enExample)
PL (1) PL1601694T3 (enExample)
PT (1) PT1601694E (enExample)
SI (1) SI1601694T1 (enExample)
TW (2) TWI439285B (enExample)
WO (1) WO2004081190A2 (enExample)
ZA (1) ZA200506879B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA05004512A (es) * 2002-10-30 2005-07-26 Genentech Inc Inhibicion de la produccion de il-17.
JP4605798B2 (ja) * 2003-03-10 2011-01-05 シェーリング コーポレイション Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
JP2007515939A (ja) * 2003-05-09 2007-06-21 セントカー・インコーポレーテツド ＩＬ−２３ｐ４０特異的免疫グロブリン由来タンパク質、組成物、方法および用途
CN1942201B (zh) * 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法；相关试剂
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
EP1756138A4 (en) * 2004-03-05 2009-07-01 Archemix Corp HUMAN CYTOKINE FAMILY BINDING APTAMERS AND THEIR USE AS THERAPEUTIC AGENTS OF AUTOIMMUNE DISEASES
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
TWI363091B (en) * 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
AU2012258409B2 (en) * 2005-06-30 2016-01-07 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
JP2009500021A (ja) * 2005-06-30 2009-01-08 アーケミックス コーポレイション サイトカインのｉｌ−１２ファミリーのポリヌクレオチドおよびポリペプチド
ES2410406T3 (es) 2005-06-30 2013-07-01 Janssen Biotech, Inc. Anticuerpos anti-IL-23, composiciones, procedimientos y usos
EP1937721B1 (en) 2005-08-25 2010-07-28 Eli Lilly And Company Anti-il-23 antibodies
HUE032131T2 (en) * 2005-08-31 2017-09-28 Merck Sharp & Dohme Constructed anti-IL-23 antibodies
JP2009507023A (ja) 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
EP3219328B1 (en) 2005-12-29 2020-06-17 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, method and uses
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
EP1882699A1 (en) * 2006-07-27 2008-01-30 Heinfried Radeke Regulation of interleukin-23
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
ATE554791T1 (de) 2007-02-23 2012-05-15 Schering Corp Gentechnisch hergestellte anti-il-23p19- antikörper
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
CA2679381A1 (en) 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
AU2008219681A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
EP2288621A4 (en) * 2007-07-06 2012-01-04 Valorisation Hsj Soc En Commandite IL23 RECEPTOR ANTAGONISTS AND THEIR USE
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2216047A4 (en) 2007-10-24 2011-12-28 Nat Univ Corp Tokyo Med & Dent Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010027767A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
US20110183859A1 (en) * 2008-09-25 2011-07-28 The United States Of America, As Represented By The Secretary, Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis
CA2740351A1 (en) * 2008-10-20 2010-04-29 Pharmatest Services Ltd. Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes
WO2010115786A1 (en) * 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
US20120269765A1 (en) * 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
EP2635601B1 (en) 2010-11-04 2016-07-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
USRE49026E1 (en) 2011-06-14 2022-04-12 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
WO2013165791A1 (en) 2012-05-03 2013-11-07 Boehringer Ingelheim International Gmbh Anti-il-23p19 antibodies
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
TWI636063B (zh) 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
US10059763B2 (en) 2014-09-03 2018-08-28 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and TNF-alpha and uses thereof
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
US11279754B2 (en) 2015-03-11 2022-03-22 Rush University Medical Center Compositions and methods for treating cancer
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
US20190269757A1 (en) 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
JP2023521870A (ja) * 2020-04-17 2023-05-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変ｉｌ－１２及びｉｌ－２３ポリペプチドとその使用
BR112022023489A2 (pt) 2020-05-21 2023-03-14 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
MXPA01005515A (es) 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
IL148300A0 (en) 1999-09-09 2002-09-12 Schering Corp Mammalian cytokines; related reagents and methods
US6756481B2 (en) 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
WO2002029060A2 (en) * 2000-10-06 2002-04-11 Immunex Corporation Hematopoietin receptors hpr1 and hpr2
US20030157105A1 (en) * 2001-05-30 2003-08-21 Carton Jill M. Anti-p40 immunglobulin derived proteins, compositions, methods and uses
JP4605798B2 (ja) * 2003-03-10 2011-01-05 シェーリング コーポレイション Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用

Also Published As

Publication number Publication date
AU2004219625B2 (en) 2010-08-19
DE602004022781D1 (de) 2009-10-08
US20100003251A1 (en) 2010-01-07
US8034341B2 (en) 2011-10-11
US20080057058A1 (en) 2008-03-06
TW201141521A (en) 2011-12-01
ZA200506879B (en) 2006-05-31
ATE440864T1 (de) 2009-09-15
MXPA05009717A (es) 2005-10-18
CL2004000467A1 (es) 2005-05-06
AU2004219625A1 (en) 2004-09-23
PL1601694T3 (pl) 2010-02-26
AU2010212372A1 (en) 2010-09-09
CY1109468T1 (el) 2014-08-13
SI1601694T1 (sl) 2010-01-29
US7282204B2 (en) 2007-10-16
AU2004219625B9 (en) 2010-12-23
TWI439285B (zh) 2014-06-01
BRPI0408247A (pt) 2006-03-01
TWI357336B (en) 2012-02-01
TW200505479A (en) 2005-02-16
CA2518262C (en) 2014-05-06
NO20054630D0 (no) 2005-10-07
PT1601694E (pt) 2009-12-03
JP2014005286A (ja) 2014-01-16
EP2108658B1 (en) 2016-06-08
HK1076477A1 (en) 2006-01-20
AU2010212372B2 (en) 2012-12-20
WO2004081190A2 (en) 2004-09-23
EP1601694B1 (en) 2009-08-26
CA2518262A1 (en) 2004-09-23
CN1759123A (zh) 2006-04-12
ES2330220T3 (es) 2009-12-07
NZ567860A (en) 2009-11-27
CN1759123B (zh) 2011-04-13
JP2006520781A (ja) 2006-09-14
US20120034219A1 (en) 2012-02-09
WO2004081190A3 (en) 2005-02-03
US20040223969A1 (en) 2004-11-11
DK1601694T3 (da) 2009-12-14
EP1601694A2 (en) 2005-12-07
EP2108658A1 (en) 2009-10-14
NO20054630L (no) 2005-10-07
JP2007197453A (ja) 2007-08-09
JP2011032275A (ja) 2011-02-17
NZ541898A (en) 2008-07-31

Similar Documents

Publication Publication Date Title
JP4605798B2 (ja) Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
US20090092604A1 (en) Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity
US20110002928A1 (en) Uses of Mammalian Cytokine; Related Reagents
JP2016034948A (ja) インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用
US20050214296A1 (en) Methods of modulating cytokine activity; related reagents
HK1130268A (en) Uses of il-23 agonists and antagonists; related reagents
HK1076477B (en) Uses of il-23 antagonists; related reagents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100929

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101004

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131015

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees